Yearly Archives: 2013

PD-Rx Pharmaceuticals: obvious cheap

16 Replies

PD-Rx Pharmaceuticals is a distributor of medication to primary care physicians. The medications are delivered prepacked from the companies warehouse so patients don’t have to see a pharmacist. But to be honest, a description of what the company is exactly doing isn’t that important for the investment case. If you look at the historical results, and the current market capitalization it becomes immediately clear that the stock is cheap. So without further ado, lets take a look at some key statistics:

Last price (Nov 4, 2013): 3.00 USD
Shares outstanding: 1,769,619
Market cap: 5.38M USD
P/B (mrq): 0.75x
P/E (ttm): 7.5x
EV/EBIT (ttm): 1.22x

Financials

An EV/EBIT ratio of just 1.22x is extremely low, and that is the combined result of a nice amount of net income with a large cash position. The company has ~75% of it’s market cap in cash and when the P/E ratio is 7.5x you get an even lower number when you switch to a metric that does account for the cash on the balance sheet. The ex-cash PE-ratio is just 2.0x: this is what I call obvious cheap! Looking at the historical financials also doesn’t uncover anything that warrants a price this low:

PD-Rx historical financials

Unfortunately the company has only the financials of the past five years available on it’s website, and that’s all you have to work with as an investor. They don’t release quarterly results and they don’t file anything with the SEC. The annual reports themselves are a quick read: there is a shareholder letter of one page, a couple of ‘nice’ graphs and financial statements (without the usual footnotes).

What we see is a business that is pretty profitable. Average return on equity was 15% the past five years while the average return on invested capital was a very respectable 23%. The company is also debt free since 2012, it remained profitable during the recent recession and the share count has remained stable the past five years. It’s hard to find anything to really hate in these numbers. Gross margins and net income are down compared to 2011, but it’s not outside the historical range.

The company also included in the 2012 annual report a graph of the amount of annual sales since the inception of the company in 1987, and in the 2011 annual report we can also find a graph of the net income since inception. Both show an encouraging long-term trend, and PD-Rx is obviously also not wasting money on graphic designers:

PD-Rx historical revenue PD-Rx historical net income

PD-Rx has been profitable since 1992. It’s hard to see how you can go wrong if you can buy a company like that for less than NCAV. Especially since it’s a safe bet that the balance sheet of PD-Rx has never been stronger than today and historical earnings would have been higher without interest expense.

The business

The numbers make it clear that the PD-Rx is cheap, and there is also a hint that it’s actually a pretty good business. Return on invested capital is high, and there is also a good track record of growing revenues and income. When you read the latest letters from the CEO to shareholders you realize that the company is not just a distributor, but that software development is an important piece of the puzzle. The software that they offer is cloud based, and once a client is using it they are presumably not switching without a good reason, and sticky customers are a good thing to have. Some relevant quotes from the recent letters (emphasis mine). From the 2010 annual report:

Our “cloud” software offering has now become a great success. Both the dispensing software and the electronic medical record are offered in that manner. We continue to work toward meaningful use criteria for the Acuity Health EMR and SureScripts certification for the e-prescribing software.

The 2011 annual report:

Our technology approach to all aspects of our business continue to keep us in the hunt; both in controlling our operational expenses and in our offerings to customers. We have made significant advances to become paperless both in our operation and as we do business with our customers. Feedback from our customers has been positive as we continue to move into the 21st century. E-pedigrees, E-invoices, and E-Statements are just a few of the ways we are streamlining our business. Our “cloud” dispensing software has been an overwhelming success and even our oldest customers are switching to the “cloud” to improve their software performance.

And the 2012 annual report (EMR stands for Electronic Medical Record):

Our technology approach continues to be refined and we have successfully integrated our “Cloud” dispensing software with the physician’s EMR. This form of integration allows every physician using an EMR to be able to send a prescription electronically for filling at the physician’s office. Dispensing has never been so easy! All the necessary patient demographic
fields are automatically filled in and with a few clicks of the mouse a patient can get their medications directly from their doctors office.

I don’t think you directly should assume that this company has a real moat, but the business quality is probably better than that of the average net-net that I discuss on this site.

Insiders

This is a part of the thesis that remains a question mark. PD-Rx does not report with the SEC, and it doesn’t disclose how many shares insiders own or how much they get paid. In theory you should be able to get access to the shareholder registry as a shareholder, but this is not something that I have tried. In practice it’s probably not easy as a small foreign shareholder who owns the shares in street name. I do think it’s likely that insiders own a decent piece of the pie since the trading liquidity in PD-Rx is very low, hinting that the free float might be low as well. But if I have a reader who can offer more insight I’d love to hear from you!

Valuation

PD-Rx doesn’t provide investors with a lot of details, but I don’t think that’s a big problem. Just based on the historical earnings and the current balance sheet we should be able to get a ballpark number. Net income has varied the past 5 years, but the $705K in income in FY2012 is close to the 5 year average of $753K (adjusted for interest expenses). While the company has shown strong growth in the past 25 years I think a more conservative no-growth assumption is reasonable given the lack of growth in recent history. If we value the average earnings at an 8.5 multiple and add the $3.9M in cash I get a valuation around $10.3M. That’s basically twice the current market capitalization, and I think there could be significantly more upside if the no-growth assumption is too conservative (it probably is).

Conclusion

PD-Rx Pharmaceuticals is perhaps not the most exciting stock, but it is cheap, generates high returns on invested capital, and the large cash position should provide downside protection. Since the company provides a limited amount of information to investors there are some questions that remain open, and it’s also not a good sign from a corporate governance perspective. At the same time the stock is without a doubt cheap.

I think that this is the kind of stock that, if you would buy a basket full of similar companies, you most likely would do well in the long run. But without knowing more about the insiders, or seeing a track-record of returning excess capital to shareholders. it’s not the kind of stock I want to bet too heavily on.

Disclosure

Author is long PDRX

Some thoughts on holdco and CEF discounts

17 Replies

My recent article on FFP received a lot of attention, but most comments were along the following lines: “sure there is a 50% discount, but what if the discounts stays at this level?”. I would say: that’s exactly what’s value investing is about! You buy cheap, and you have to have some faith that at some point in time the market will recognize how much its truly worth. This is what Benjamin Graham had to say about the subject in 1955 to a Senate commission (the full transcript is available online):

The Chairman: … One other question and I will desist. When you find a special situation and you decide, just for illustration, that you can buy for 10 and it is worth 30, and you take a position, and then you cannot realize it until a lot of other people decide it is worth 30, how is that process brought about – by advertising, or what happens?

Mr. Graham: That is one of the mysteries of our business, and it is a mystery to me as well as to everybody else. We know from experience that eventually the market catches up with value. It realizes it in one way or another.

I’m not saying that the discount will completely be eliminated in time, because there are valid reasons why a holding company or a closed-end fund should trade at a discount. These are overhead costs, tax inefficiencies and potential value destruction. In general overhead costs for holding companies are low, while closed-end funds incur higher costs because there is an ‘active investment manager’ that gets a fee based on AUM. Holding companies on the other hand are often less tax efficient. Dividends cannot always be passed through from the operating companies to the holding company in a tax free manner. In most jurisdictions this is not a major issue: It is usually possible to pass through dividends in a tax free manner if the holding company has a sufficiently big stake in the operating company.

The last important ingredient that should determine the discount is whether or not the manager is adding value, subtracting value, or is value neutral. I think the best assumption is usually the last one. Most CEF’s invest for example in large cap companies: they don’t underperform the market before trading costs in the long-term, but they also don’t deliver outperformance. If you already account for trading costs under the overhead the manager probably doesn’t add further negative performance. Holding companies are very often passive vehicles, and since they are passive there is neither value destruction nor creation. Rella is a nice example of a holding company that is actually creating value, simply by buying back undervalued shares.

Discount fluctuations

Both CEF discounts and holdco discounts usually vary over time. Sometimes they are small, and sometimes they are big. My thesis is that these fluctuations can be partly explained by the perceived attractiveness of the underlying assets, general investor sentiment and the fact that both holdco’s and CEF’s have a fixed supply of shares outstanding.

I wrote for example about mortgage closed-end funds two months ago. Rising interest rates resulted in declining prices for the underlying assets and at the same time the number of investors willing to invest in CEF with these type of assets also declined. As a result the discounts to NAV increased at the same time as NAV’s declined. If the market would be efficient this would be hard to explain since the lower underlying asset prices should already have reflected the bad news.

The reason that this doesn’t happen is that there is no (easy) arbitrage between share price and NAV. So when investors want to exit anyway only one thing can happen: the discount increases. Similar mechanics are at work behind the holdco discounts, except that there is even less of a possibility of arbitrage between share price and underlying value. When a closed-end fund starts trading at a huge discount activist investors can usually acquire a big enough stake to push for liquidation while holdco’s are often tightly controlled by their founders. They might want to take advantage of the discount by buying back shares at some point, but it’s also possible that you simply have to wait for sentiment to change.

Possible returns

I have no idea when investor sentiment is going to change for FFP, but I do think it will probably change at some point in time. Between 2007 and today the discount varied between 30 and 50%, and in the next five or ten years I would be surprised if it wouldn’t move back to the bottom of this range at some point in time. And you shouldn’t underestimate the amount of alpha you can create when this does happen.

If it would take 10 full years for the discount to shrink from 50% to 30% you still generate 2.9% alpha annualized (this is after accounting for 0.5% in overhead costs). If it takes ‘just’ 5 years you are looking at 6.4% annualized alpha. I don’t know about you, but that’s certainly attractive enough for me!

Disclosure

Long FFP.PA and RELLA.CO

Historical FFP discount to NAV

Leave a reply

A reader asked in what range the FFP discount to NAV has been historically, and that seemed like a good question to answer with a graph. I couldn’t easily find historical NAV data from before 2006, but what we do see is that the discount has been smaller in the past, and that the current discount of nearly 50% is at the top of the historical range. It would also not surprise me if the discount has been smaller than 30% if we would look further back.

FFP historical discountWhile this is of course encouraging to see I don’t think it’s extremely important. A 50% discount is a 50% discount, regardless of the past, and I have looked at enough holding companies to know that this kind of discount is big.

Disclosure

Author is long FFP.PA

FFP: investing in France at a 50% discount

25 Replies

Societe Fonciere, Financiere et de Participations or simply FFP is a diversified French holding company that is trading at a discount of roughly 50% to it’s NAV. The biggest shareholder in the company is the Peugeot family with a 79.2% stake. So while FFP has a €1.08B market cap the free float is just €225 million. Given the fact that the FFP is majority owned by the Peugeot family it shouldn’t come as a surprise that the largest position is also in the company Peugeot, accounting for almost 30% percent of gross asset value. The other assets consist mostly of publicly traded French companies, private equity investments and real estate. Given the large amount (>83%) of publicly traded assets inside FFP it’s easy to calculate an updated net asset value, confirming the big discount:

FFP NAV spreadsheet

The spreadsheet you see here is publicly accessible on Google Drive using this link and updates automatically all share prices and the current discount. Not all assets in FFP are publicly traded, and since the CAC 40 index is up ~15% since the end of June the real discount to NAV is most likely hitting 50% at this moment. This is basically the whole investment thesis! I could write thousands of words about the valuation of the individual companies inside FFP, but the truth is that I don’t really care. The companies that FFP owns have market caps in the billions of euro’s, and I do trust the market to some degree.

What’s positive to see is that FFP appears to have a good track record with their investments outside Peugeot. As you might know the family business isn’t doing very well these days, and if you would have invested in Peugeot 5 years ago you would have lost half your money. If you would have invested in FFP on the other hand you would have made more than 20%, a remarkable achievement given the huge historical stake in Peugeot.

FFP performance relative vs Peugeot

An investment without a catalyst

What I do want to discuss is why I like an investment at a big discount in a holding company, even though I don’t expect that this discount will disappear anytime soon. The Peugeot family owns almost 80% of the holding company so there is no way an outside investor can pressure the family to do something to eliminate the discount, and the family is presumably not extremely interested in the market price of FFP since they are holding this for the very long term. FFP is the vehicle that allows them to control Peugeot SA: their legacy.

I don’t think this really matters though. Even if the discount would never get smaller you buy a company that can support a dividend steam that is twice as high as the underlying assets. And that is what ultimately determines intrinsic value: the dividend stream back to shareholders. You don’t need to sell a stock at a higher price to realize value: if you buy cheap and just hold you will simply enjoy an above average yield.

While there is nothing wrong with holding a stock till infinity I actually don’t think that you have to do this. At some point in time the market will probably realize that a 50% discount isn’t warranted. Last year FFP didn’t pay a dividend because of the poor results at Peugeot and the re-initiation of a dividend could possibly act as a catalyst.

I also assume that the Peugeot family doesn’t hate money. The undervalued shares represent an easy opportunity to make money if they start a repurchase program. You also have to figure that there is probably going to be some point in time when the Peugeot family wants liquidity. They would be stupid to sell their FFP shares at a 50% discount when they could for example divest some assets and realize NAV. Since I think they will care about the NAV discount at some undetermined point in the future you can expect that it will eventually be eliminated. It’s going to take a lot of patience, but I don’t mind that if I’m owning an asset that has intrinsically a yield twice as high as the market average.

Conclusion

The investment thesis in FFP is extremely simple. The holding company trades at a 50% discount to NAV, and I don’t think such a large discount is warranted. Luckily I believe that the simpler the investment thesis, the better, and it doesn’t get any simpler than this!

Rating: on a scale from one to five I’m going to give this idea two stars. The thesis in FFP shares many similarities with Burelle: both are French, family controlled holding companies at a ~50% discount with a focus on the automotive industry. An identical rating is logical.

Disclosure

Author is long FFP.PA

Incentives matter

11 Replies

I suspect that a lot of my readers also visit the Whopper Investments blog, so you might have noticed that I gave this post an identical title as his last one: Incentives matter. Whopper summarizes my thinking about the subject in the following sentence: “I believe that people are always going to do what’s in their best interest”.

This is of course very important when you scrutinize what insiders are doing at a company, but it is equally true when you read an article online. What are the incentives of the author? I recently wrote a post for Seeking Alpha about Deswell Industries. For regular readers of my blog not a new name since I own it since the beginning of 2012. At the time I spend little time about looking at the underlying business, my main concern was whether or not the company was potentially a fraud since it’s doing business in China.

So my incentives for writing this post, and publishing it on SA:

  1. Reviewing and updating my investment thesis
  2. Gain some exposure on SA, maybe attract some new readers to my blog
  3. Last but not least: make a few bucks

SA pays authors a minimum of $150 dollar for a good article on a under-followed micro/small cap while there is minimum payment of $500 dollar for an article that is selected as an “Alpha Rich” idea. So what is your incentive as a writer: to write a piece that convinces the SA editors that the stock offers an asymmetrical risk/reward ratio! It’s no longer about publishing the most balanced research. Of course you should mention some negatives because you sound smarter if you do, but it’s easy to downplay a specific issue. I wish it wouldn’t be true, but after writing the article I realized how you are tempted to do it. Even without the money the incentive would be there: it’s also an ego thing.

In the case of Deswell Industries I don’t think it would have been too hard to write an article that sounded a lot better. You have the downside part of the story covered with the large amount of cash on the balance sheet, and it’s easy to write for example a nice story on how the business has decent long-term prospects (not impossible) or how the leasehold land of the company could potentially be a very valuable asset (for the record: I don’t think this is very likely, but you see on SA a reader that is trying to make this case). It doesn’t even matter if you fool the SA editors or not, the end result is the same.

So what does this mean for me?

My number one motivation of starting this blog is to improve my investment process and skills. I often think about my write-ups as a sort of public visible checklist (without the checks). By writing an ‘exclusive’ article for SA I’m giving myself a competing incentive, and that is a dangerous thing because it’s already easy enough to be biased towards your own idea’s. So you don’t have to expect a lot of other SA articles from me in the future, although I might occasionally review an existing position (or maybe write about something I don’t own).

A slightly related topic is my decision to keep the blog free from advertisements. That would also introduce a competing incentive: away from the quality of posts and towards the quantity of posts. I don’t think advertising revenue would be material anyway, so no reason to do something that subtracts from the main goal of the blog.

What should it mean for you?

Nothing! You should be doing your own thinking and research anyway. But when you read something it still pays to think about the incentives of the writer, because it can tell you where you could start looking to find the weak points in the thesis. Unfortunately this means on SA that authors have an incentive to make the story sound as positive and convincing as possible. I understand why they are doing this, because it’s at the same time also an incentive for people to write true “Alpha Rich” articles, and I think they are succeeding with that part of the equation. I do see more interesting articles appearing than in the past.